FDA Prioritizes New Technologies, Nano Included, In Regulatory Science Plan
This article was originally published in The Rose Sheet
Executive Summary
FDA plans to invest in eight priority areas for regulatory science, with the goal of improving its handle on emerging technologies such as nanotechnology, elevating the quality of clinical trial data and developing better tools for reviewing manufacturing systems, according to a strategic plan.
You may also be interested in...
Trade Group Urges FDA To Look Beyond Scale In Regulating Nanotechnology
FDA should not use size alone to regulate nanotechnology, the Consumer Healthcare Products Association says.
FDA Committed To Advancing Its Regulatory Science Capacity
FDA cites "advances in the application of nanotechnology" among scientific "breakthroughs" that are revolutionizing the health-care community's ability to treat disease, making the notion of personalized care a reality and demanding more FDA involvement
Jurors' Answers In FTC's Prevagen Complaint Might Burst A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.